Regeneron Pharmaceuticals REGN Business Segments
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| Revenue by Product | ||||||
| Lynozyfic | $11.2M— | —— | —— | —— | $0— | |
| Other products | $31.3M— | $9.3M— | $800K— | $0— | $0— | |
| (Regeneron's obligation for its share of Sanofi R&D expenses)/reimbursements of R&D expenses, net | -$16.7M-7.7% | -$12.6M-11.5% | -$23.5M-201% | -$18M-97.8% | -$15.5M+16.7% | |
| Reimbursement For Manufacturing Of Commercial Supplies | $154.3M-6.5% | $154.3M-9.1% | $161.5M-7.8% | $161.5M+2.7% | $165M+56.0% | |
| Reimbursement Of Commercialization Related Expenses | $184.1M+15.6% | $193.5M-1.3% | $182.6M+8.0% | $194M+28.6% | $159.2M+14.1% | |
| Cost of goods sold, collaboration and contract manufacturing by Product | ||||||
| Collaborationand Contract Manufacturing | $296M+48.9% | $265.9M+11.4% | $240.6M+5.2% | $254.6M+14.5% | $198.8M+2.8% | |
| Product | $373.4M+40.6% | $318.7M-2.5% | $281M+7.1% | $275.6M+6.9% | $265.5M+10.4% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How does Regeneron Pharmaceuticals break its business down?
- Regeneron Pharmaceuticals (REGN) reports revenue by product across 5 parts — Lynozyfic, Other products, (Regeneron's obligation for its share of Sanofi R&D expenses)/reimbursements of R&D expenses, net, Reimbursement For Manufacturing Of Commercial Supplies and Reimbursement Of Commercialization Related Expenses. Each is extracted from the segment footnotes and tracked over time.
- Where does Regeneron Pharmaceuticals's segment data come from?
- Segment breakdowns are pulled from the segment footnotes in Regeneron Pharmaceuticals's SEC filings (the XBRL dimensional tags), so every line ties back to a reported figure. Switch between quarterly, annual, and TTM, or open any segment for its full history.
